Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer_journal/hyperprogressive-disease-and-early-hypereosinophilia-after-anti-pd-1-4FAtevTLhi
References (17)
-
L. Gaba, I. Victoria, E. Pineda, Aranzazu Fernández, F. Aya, A. Prat, A. Arance (2015)
Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.Journal of Clinical Oncology, 33
-
J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel, L. Zitvogel, N. Chaput, Séverine Roy, A. Eggermont, É. Routier, C. Robert (2013)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.Annals of oncology : official journal of the European Society for Medical Oncology, 24 6
-
R. Carretero, I. Sektioglu, N. Garbi, Oscar Salgado, P. Beckhove, G. Hämmerling (2015)
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cellsNature Immunology, 16
-
A. Moreira, W. Leisgang, G. Schuler, L. Heinzerling (2017)
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.Immunotherapy, 9 2
-
S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque, S. Postel-Vinay, N. Chaput, A. Eggermont, A. Marabelle, J. Soria, C. Ferté (2016)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical Cancer Research, 23
-
A. Bernard-Tessier, P. Jeanville, S. Champiat, J. Lazarovici, A. Voisin, C. Mateus, O. Lambotte, M. Annereau, J. Michot (2017)
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.European journal of cancer, 81
-
B. Weide, A. Martens, J. Hassel, C. Berking, M. Postow, Kees Bisschop, E. Simeone, J. Mangana, B. Schilling, A. Giacomo, N. Brenner, K. Kähler, L. Heinzerling, R. Gutzmer, A. Bender, C. Gebhardt, E. Romano, F. Meier, P. Martus, M. Maio, C. Blank, D. Schadendorf, R. Dummer, P. Ascierto, G. Hospers, C. Garbe, J. Wolchok (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabClinical Cancer Research, 22
-
Zan Huang, J. Xin, J. Coleman, Hua Huang (2005)
IFN-γ Suppresses STAT6 Phosphorylation by Inhibiting Its Recruitment to the IL-4 Receptor1The Journal of Immunology, 174
-
C. Schindler, D. Levy, T. Decker (2007)
JAK-STAT Signaling: From Interferons to Cytokines*Journal of Biological Chemistry, 282
-
Davina Wu, Ari Molofsky, Hong-Erh Liang, R. Ricardo-Gonzalez, H. Jouihan, Jennifer Bando, A. Chawla, R. Locksley (2011)
Eosinophils Sustain Adipose Alternatively Activated Macrophages Associated with Glucose HomeostasisScience, 332
-
S. Koyama, Esra Akbay, Yvonne Li, G. Herter-Sprie, Kevin Buczkowski, W. Richards, L. Gandhi, A. Redig, S. Rodig, H. Asahina, Robert Jones, Meghana Kulkarni, M. Kuraguchi, Sangeetha Palakurthi, P. Fecci, B. Johnson, P. Jänne, J. Engelman, Sidharta Gangadharan, D. Costa, G. Freeman, R. Bueno, F. Hodi, G. Dranoff, Kwok-kin Wong, P. Hammerman, P. Hammerman (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsNature Communications, 7
-
W. Peng, Chengwen Liu, Chunyu Xu, Y. Lou, J. Chen, Yan Yang, H. Yagita, W. Overwijk, G. Lizée, L. Radvanyi, P. Hwu (2012)
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.Cancer research, 72 20
-
(2012)
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-c inducible chemokines -
M. Amin, S. Edge, F. Greene, D. Byrd, R. Brookland, M. Washington, J. Gershenwald, C. Compton, K. Hess, D. Sullivan, J. Jessup, J. Brierley, L. Gaspar, R. Schilsky, C. Balch, D. Winchester, Elliot Asare, M. Madera, Donna Gress, L. Meyer (2002)
AJCC Cancer Staging Manual -
E. Lipson, P. Forde, H. Hammers, L. Emens, J. Taube, S. Topalian (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment.Seminars in oncology, 42 4
-
S. Kato, A. Goodman, V. Walavalkar, D. Barkauskas, A. Sharabi, R. Kurzrock (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth RateClinical Cancer Research, 23
-
Lin Liu, M. Bates, N. Jarjour, W. Busse, P. Bertics, E. Kelly (2007)
Generation of Th1 and Th2 Chemokines by Human Eosinophils: Evidence for a Critical Role of TNF-α1The Journal of Immunology, 179
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by The Author(s)
- Subject
- Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
- ISSN
- 2199-1162
- eISSN
- 2198-977X
- DOI
- 10.1007/s40800-018-0078-z
- Publisher site
- See Article on Publisher Site
Abstract
Hyperprogressive disease (HPD) has been recently proposed as a new pattern of progression in patients treated with immune checkpoint inhibitors (ICIs). Until now, no biological marker has been found to predict this accelerated tumour growth. We describe the case of a 62-year-old women who experienced a marked increase in absolute eosinophil count (AEC) concurrently with a huge radiological progression after the first nivolumab dose in absence of other immune-related adverse events (irAEs). Further investigations are needed to establish the role of early hypereosinophilia as a marker of progression and to identify patients who might not benefit from ICI treatment.
Journal
Drug Safety - Case Reports – Springer Journals
Published: Mar 13, 2018